We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Onpattro

News List

Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran) pharmaceutical-business-review
March 30, 2020
Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, and Gen, a GMP-certified pharmaceutical company specializing in rare diseases ...
Alnylam partners with Medison to offer Onpattro in Israel pharmaceutical-technology
January 23, 2019
US-based Alnylam Pharmaceuticals has signed an exclusive agreement with Medison Pharma to commercialise its RNAi therapeutic Onpattro in Israel....
Dicerna agrees another gene-silencing deal, this time with Lilly pharmaphorum
December 18, 2018
Eli Lilly has agreed a broad collaboration with Dicerna, sealing the deal with a $100 million equity stake in the RNA interference specialist.
NICE rejects NHS funding for Tegsedi, Onpattro pharmatimes
December 13, 2018
The National Institute for Health and Care Excellence has issued draft guidelines rejecting NHS funding for two therapies that treat the rare inherited condition hereditary transthyretin-related amyliodsis (hATTR).